RALEIGH, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to [...]
We are dedicated to
the future of clinical development
and to every life it saves.
Learn more about why we do what we do, and what we can do for you. Click to read our story.
See the latest interactions from our social media
With more drugs on the market than ever before, the need to demonstrate real-world evidence of product effectiveness, safety and value has increased. PRA develops comprehensive study designs that fully demonstrate our many years of #postmarketing experience and expertise. Our #LatePhase team includes 16+ spoken languages, 245+ post-secondary degrees and over 250 studies in the past 5 years. Click here to learn more: http://bit.ly/1o8WWkW
Read the latest updates from our PR department
$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015 First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, [...]
RALEIGH, N.C., April 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. [...]
Explore the latest resources uploaded to our media library
Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter
PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.
PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...
A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.
Find out what's happening next on PRA's event schedule
The DIA China Annual Meeting as the largest interdisciplinary event in Asia that brings together a global network of life sciences professionals to foster innovation that leads to the development of safe and effective products and therapies to patients. Professionals at all levels involved in the drug discovery, development, and life cycle management of health […]
This must-attend event gathers hepatologists from The Czech Republic to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.
Opioids are effective tools when used properly in the management of pain. They are cost effective and allow increased numbers of patients to return to active productive lives in society. Yet, while opioids have been with us for over 4000 years, the landscape of opioid therapies is rapidly evolving. Federal and state regulations are swiftly […]